The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

Similar Items

• The different path of T790M-positive EGFR-mutant lung cancer
  od: Yoon, Shinkyo, i dr.
  Izdano: (2018)
• Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
  od: Kwon, Byoung Soo, i dr.
  Izdano: (2017)
• The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
  od: Fu-Tsai Chung, i dr.
  Izdano: (2015-01-01)
• The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
  od: Chung, Fu-Tsai, i dr.
  Izdano: (2015)
• Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
  od: So, Kwang Sup, i dr.
  Izdano: (2014)